UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP

Molecular cancer research, 2014-12, Vol.12 (12), p.1755-1766

2014

Volltextzugriff (PDF)

Role of CYP3A5 in Modulating Androgen Receptor Signaling and Its Relevance to African American Men with Prostate Cancer

Cancers, 2020-04, Vol.12 (4), p.989

2020

Volltextzugriff (PDF)

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma

European urology oncology, 2024-08, Vol.7 (4), p.933-943

2024

Volltextzugriff (PDF)

Comparison of Circulating MicroRNA 141 to Circulating Tumor Cells, Lactate Dehydrogenase, and Prostate-Specific Antigen for Determining Treatment Response in Patients With Metastatic Prostate Cancer

Clinical genitourinary cancer, 2011-09, Vol.9 (1), p.39-45

2011

Volltextzugriff (PDF)

Circulating Tumor Cells as a Predictive Biomarker in Patients With Hormone-sensitive Prostate Cancer

Clinical genitourinary cancer, 2011-09, Vol.9 (1), p.31-38

2011

Volltextzugriff (PDF)

Neprilysin Inhibits Angiogenesis via Proteolysis of Fibroblast Growth Factor-2

The Journal of biological chemistry, 2006-11, Vol.281 (44), p.33597-33605

2006

Volltextzugriff (PDF)

Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial

Clinical cancer research, 2022-08, Vol.28 (15), p.3248-3255

2022

Volltextzugriff (PDF)

Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer

Clinical cancer research, 2022-06, Vol.28 (11), p.2237-2247

2022

Volltextzugriff (PDF)

The HDAC6 Inhibitor Tubacin Induces Release of CD133+ Extracellular Vesicles From Cancer Cells

Journal of cellular biochemistry, 2017-12, Vol.118 (12), p.4414-4424

2017

Volltextzugriff (PDF)

Urothelial Bladder Carcinoma With Choriocarcinomatous Differentiation Presenting With a False-Positive Pregnancy Test

The American journal of the medical sciences, 2013-09, Vol.346 (3), p.256-258

2013

Volltextzugriff (PDF)

A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors

Journal of immunotherapy (1997), 2011-09, Vol.34 (7), p.556-567

2011

Volltextzugriff (PDF)

Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature

Journal of medical case reports, 2009-09, Vol.3 (1), p.9110-9110

2009

Volltextzugriff (PDF)

Targeting DNA damage response to overcome taxane resistance

Journal of clinical oncology, 2018-02, Vol.36 (6_suppl), p.312-312

2018

Volltextzugriff (PDF)

Abstract B017: Role of CYP3A5 in modulating androgen receptor signaling and its relevance in African American prostate cancer patients

Cancer epidemiology, biomarkers & prevention, 2020-06, Vol.29 (6_Supplement_1), p.B017-B017

2020

Volltextzugriff (PDF)

Novel Antibody Approaches for T-Cell Lymphomas

Clinical lymphoma & myeloma, 2008-12, Vol.8, p.S193-S198

2008

Volltextzugriff (PDF)

Abstract 1311A: CYP3A5 regulation of androgen receptor signaling: Relevance in African American prostate cancer patients and its development as novel target

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.1311-1311A

2019

Volltextzugriff (PDF)

Abstract 4650: Effect of prescription CYP3A inducers and inhibitors on response to anti-androgen therapy in prostate cancer

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4650-4650

2016

Volltextzugriff (PDF)

Abstract B001: CYP3A5 promotes AR downstream signaling and contributes to therapeutic resistance

Cancer research (Chicago, Ill.), 2018-08, Vol.78 (16_Supplement), p.B001-B001

2018

Volltextzugriff (PDF)

Abstract B48: Effect of concomitant CYP3A5-modulating drugs on androgen-receptor signaling in African American men undergoing androgen deprivation therapy

Cancer epidemiology, biomarkers & prevention, 2018-07, Vol.27 (7_Supplement), p.B48-B48

2018

Volltextzugriff (PDF)

Abstract 3130: CYP3A5 positively regulates androgen receptor signaling in prostate cancer cells: Potential for therapeutic targeting

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.3130-3130

2017

Volltextzugriff (PDF)

A phase 2, multicenter, parallel-group, open-label study of vudalimab (XmAb20717), a PD-1 x CTLA-4 bispecific antibody, alone or in combination with chemotherapy or targeted therapy in patients with molecularly defined subtypes of metastatic castration-resistant prostate cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS5097-TPS5097

2022

Volltextzugriff (PDF)

Mapping of the molecular determinants involved in the interaction between eps15 and AP-2

Cancer research (Chicago, Ill.), 1997-01, Vol.57 (2), p.240-245

1997

Volltextzugriff (PDF)

Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature

Journal of medical case reports, 2009-09, Vol.3 (1), p.9110-9110

2009

Volltextzugriff (PDF)

Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial

Clinical cancer research, 2022-08, Vol.28 (15), p.3248-3255

2022

Volltextzugriff (PDF)

1 – 25 von 60

Suche als RSS-Feed

Aktive Filter

ThemaProstate Cancer

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(55)

Publikationsform

Artikel
(58)
magazinearticle
(2)

Sprache

Englisch
(60)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP

Role of CYP3A5 in Modulating Androgen Receptor Signaling and Its Relevance to African American Men with Prostate Cancer

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma

Comparison of Circulating MicroRNA 141 to Circulating Tumor Cells, Lactate Dehydrogenase, and Prostate-Specific Antigen for Determining Treatment Response in Patients With Metastatic Prostate Cancer

Circulating Tumor Cells as a Predictive Biomarker in Patients With Hormone-sensitive Prostate Cancer

Neprilysin Inhibits Angiogenesis via Proteolysis of Fibroblast Growth Factor-2

Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial

Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer

The HDAC6 Inhibitor Tubacin Induces Release of CD133+ Extracellular Vesicles From Cancer Cells

Urothelial Bladder Carcinoma With Choriocarcinomatous Differentiation Presenting With a False-Positive Pregnancy Test

A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors

Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature

Targeting DNA damage response to overcome taxane resistance

Abstract B017: Role of CYP3A5 in modulating androgen receptor signaling and its relevance in African American prostate cancer patients

Novel Antibody Approaches for T-Cell Lymphomas

Abstract 1311A: CYP3A5 regulation of androgen receptor signaling: Relevance in African American prostate cancer patients and its development as novel target

Abstract 4650: Effect of prescription CYP3A inducers and inhibitors on response to anti-androgen therapy in prostate cancer

Abstract B001: CYP3A5 promotes AR downstream signaling and contributes to therapeutic resistance

Abstract B48: Effect of concomitant CYP3A5-modulating drugs on androgen-receptor signaling in African American men undergoing androgen deprivation therapy

Abstract 3130: CYP3A5 positively regulates androgen receptor signaling in prostate cancer cells: Potential for therapeutic targeting

A phase 2, multicenter, parallel-group, open-label study of vudalimab (XmAb20717), a PD-1 x CTLA-4 bispecific antibody, alone or in combination with chemotherapy or targeted therapy in patients with molecularly defined subtypes of metastatic castration-resistant prostate cancer

Mapping of the molecular determinants involved in the interaction between eps15 and AP-2

Carcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature

Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial

Blood biomarkers and association with clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC): prespecified longitudinal analysis from the ACIS study of apalutamide (APA) or placebo combined with abiraterone acetate plus prednisone (AAP)

Aktive Filter

Suchergebnisse filtern